Dyne Therapeutics (DYN) EBIT (2019 - 2026)
Dyne Therapeutics (DYN) posted quarterly EBIT of -$181.7 million for Q2 2026, down 56.89% year-over-year from -$421.4 million in Q2 2025, and down 45.01% quarter-over-quarter from -$125.3 million in Q1 2026.
Dyne Therapeutics (DYN) EBIT (2019 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has reported EBIT for 8 consecutive years, with -$181.7 million the latest figure, recorded in Q2 2026.
- In Q2 2026, EBIT fell 56.89% year-over-year to -$181.7 million; the TTM figure through Jun 2026 stood at -$537.0 million (down 21.8% YoY), while the FY2025 annual figure was -$468.2 million, down 36.15% from the prior year.
- EBIT retreated to -$181.7 million in Q2 2026 per DYN's latest filing, from -$125.3 million in the prior quarter.
- Across five years, EBIT topped out at -$35.8 million in Q1 2022 and bottomed at -$181.7 million in Q2 2026.
- Historically, EBIT has averaged -$85.1 million across 5 years, with a median of -$70.6 million in 2024.
- Annual changes were most pronounced in 2022 — EBIT climbed 22.74% — and 2025, when it sank 76.95%.
- Dyne Therapeutics' EBIT stood at -$40.1 million in 2022, then plunged by 68.61% to -$67.7 million in 2023, then slumped by 43.46% to -$97.1 million in 2024, then decreased by 19.59% to -$116.1 million in 2025, then sank by 56.43% to -$181.7 million in 2026.
- Business Quant data shows DYN's EBIT at -$181.7 million in Q2 2026, -$125.3 million in Q1 2026, and -$116.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Dyne Therapeutics | 4.26 Bn | 4.26 Bn | - | -181.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -181.66 Mn |
| Mar 31, 2026 | -125.28 Mn |
| Dec 31, 2025 | -116.13 Mn |
| Sep 30, 2025 | -113.89 Mn |
| Jun 30, 2025 | -115.79 Mn |
| Mar 31, 2025 | -122.37 Mn |
| Dec 31, 2024 | -97.11 Mn |
| Sep 30, 2024 | -105.57 Mn |
| Jun 30, 2024 | -71.96 Mn |
| Mar 31, 2024 | -69.16 Mn |
| Dec 31, 2023 | -67.69 Mn |
| Sep 30, 2023 | -62.27 Mn |
| Jun 30, 2023 | -66.74 Mn |
| Mar 31, 2023 | -45.46 Mn |
| Dec 31, 2022 | -40.15 Mn |
| Sep 30, 2022 | -42.28 Mn |
| Jun 30, 2022 | -52.76 Mn |
| Mar 31, 2022 | -35.78 Mn |
| Dec 31, 2021 | -51.96 Mn |
| Sep 30, 2021 | -42.77 Mn |